Novartis Oncology has expanded its patient access programs to incorporate Tasigna® (nilotinib), a next-generation tyrosine kinase inhibitor designed to meet the needs of the few adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic or accelerated phases that cannot tolerate, do not respond to, or develop resistance to Glivec.

In countries where full donation is the only appropriate path to access to Tasigna, Novartis, in partnership with The Max Foundation, has begun to establish TIPAP to ensure that patients can receive this valuable medication.

Full donation of Tasigna through TIPAP will be available to Glivec patients who meet both clinical and economic criteria. Leading experts in CML around the world have developed and published medical criteria to determine when it is appropriate to prescribe Tasigna for particular patients. Economic eligibility for full donation of medicine through TIPAP is consistent with criteria employed for GIPAP.

New access models will facilitate partial donation of Tasigna to other patients in countries where full donation is not applicable.